标题
Syk inhibitors in clinical development for hematological malignancies
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 10, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-07-28
DOI
10.1186/s13045-017-0512-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective
- (2017) Isabelle Rivière et al. MOLECULAR THERAPY
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- Therapeutic T cell engineering
- (2017) Michel Sadelain et al. NATURE
- Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
- (2017) Arnab Ghosh et al. NATURE MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data
- (2016) Arie Barlev et al. ADVANCES IN THERAPY
- Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)
- (2016) Betty Lam et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL
- (2016) P. M. Barr et al. BLOOD
- The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
- (2016) Matthew D. Blunt et al. CLINICAL CANCER RESEARCH
- A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
- (2016) Ian W. Flinn et al. EUROPEAN JOURNAL OF CANCER
- Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients
- (2016) Christine Braegelmann et al. EXPERIMENTAL DERMATOLOGY
- Inhibition of spleen tyrosine kinase (syk) suppresses renal fibrosis through anti-inflammatory effects and down regulation of the MAPK-p38 pathway
- (2016) Kuan-Hsing Chen et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia
- (2016) Bo Cai et al. Journal of Hematology & Oncology
- Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
- (2016) Weijie Ma et al. Journal of Hematology & Oncology
- Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Second-generation inhibitors of Bruton tyrosine kinase
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial
- (2016) Michael L Wang et al. LANCET ONCOLOGY
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia
- (2015) J. Sharman et al. BLOOD
- Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma
- (2015) Michelle Furtado et al. BRITISH JOURNAL OF HAEMATOLOGY
- The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis
- (2015) Guray Can et al. Journal of Crohns & Colitis
- Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
- (2015) Rossana Maffei et al. Journal of Hematology & Oncology
- Targeting Wnt pathway in mantle cell lymphoma-initiating cells
- (2015) Rohit Mathur et al. Journal of Hematology & Oncology
- Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells
- (2015) Dongmei Fan et al. Journal of Hematology & Oncology
- Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia
- (2015) Kanti R. Rai Journal of Hematology & Oncology
- AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
- (2015) Shundong Cang et al. Journal of Hematology & Oncology
- Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- Bispecific antibodies and their applications
- (2015) Gaowei Fan et al. Journal of Hematology & Oncology
- The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo
- (2015) Min-Wu Chao et al. Journal of Hematology & Oncology
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia
- (2015) Zhengshan Chen et al. NATURE
- Ibrutinib in Refractory Classic Hodgkin's Lymphoma
- (2015) Mehdi Hamadani et al. NEW ENGLAND JOURNAL OF MEDICINE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma
- (2015) Jiao Ma et al. Oncotarget
- A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor
- (2015) Russell T Burke et al. Oncotarget
- SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
- (2014) Alexandre Puissant et al. CANCER CELL
- Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase
- (2014) Kevin S. Currie et al. JOURNAL OF MEDICINAL CHEMISTRY
- Ibrutinib Resistance in Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetics and Efficacy of the Spleen Tyrosine Kinase Inhibitor R406 after Ocular Delivery for Retinoblastoma
- (2014) Eleanor M. Pritchard et al. PHARMACEUTICAL RESEARCH
- Therapeutic Potential of Spleen Tyrosine Kinase Inhibition for Treating High-Risk Precursor B Cell Acute Lymphoblastic Leukemia
- (2014) T. Perova et al. Science Translational Medicine
- Getting Syk: spleen tyrosine kinase as a therapeutic target
- (2014) Robert L. Geahlen TRENDS IN PHARMACOLOGICAL SCIENCES
- Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
- (2014) Michael E. Weinblatt et al. Arthritis & Rheumatology
- The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation
- (2013) M Skinner et al. BRITISH JOURNAL OF PHARMACOLOGY
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors
- (2012) Rajinder Singh et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fostamatinib, a Syk-Kinase Inhibitor, Does Not Affect Methotrexate Pharmacokinetics in Patients With Rheumatoid Arthritis
- (2011) Muhammad Baluom et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Spleen tyrosine kinase inhibitors—novel therapies for RA?
- (2011) José A. Gómez-Puerta et al. Nature Reviews Rheumatology
- The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E - TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling
- (2010) M. Suljagic et al. BLOOD
- Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia
- (2010) M. Buchner et al. BLOOD
- Spleen tyrosine kinases: biology, therapeutic targets and drugs
- (2010) Mauro Riccaboni et al. DRUG DISCOVERY TODAY
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia
- (2009) Maike Buchner et al. CANCER RESEARCH
- Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial
- (2008) Michael E. Weinblatt et al. ARTHRITIS AND RHEUMATISM
- Molecular Mechanism of the Syk Activation Switch
- (2008) Emily Tsang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
- (2008) Bruce D. Cheson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of [3-(1-methyl-1H-indol-3-yl-methylene)-2-oxo-2, 3-dihydro-1H-indole-5-sulfonamide] (OXSI-2), as a Syk-selective inhibitor in platelets
- (2007) Kamala Bhavaraju et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Syk inhibitors as treatment for allergic rhinitis
- (2007) Esteban S. Masuda et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now